View : 35 Download: 0
Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)
- Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)
- Kim Y.-J.; Park W.; Ha B.; Park B.; Joo J.; Kim T.H.; Park I.H.; Lee K.S.; Lee E.S.; Shin K.H.; Kim H.; Yu J.I.; Choi D.H.; Huh S.J.; Wee C.W.; Kim K.; Park K.R.; Kim Y.B.; Ahn S.J.; Lee J.H.; Kim J.H.; Chun M.; Lee H.-S.; Kim J.S.; Cha J.
- Ewha Authors
- 김규보; 박경란
- SCOPUS Author ID
- 김규보; 박경란
- Issue Date
- Journal Title
- Cancer Research and Treatment
- Cancer Research and Treatment vol. 49, no. 4, pp. 927 - 936
- Breast neoplasms; Disease-free survival; Radiotherapy; Recurrence; Survival; Taxane
- Korean Cancer Association
- SCIE; SCOPUS; KCI
- Document Type
- Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3. © 2017 by the Korean Cancer Association.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.